MARKET WIRE NEWS

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

Source: SeekingAlpha

2025-03-17 10:50:56 ET

NRx Pharmaceuticals, Inc. (NRXP)

Q4 2024 Earnings Conference Call

March 17, 2025 08:30 AM ET

Company Participants

Matthew Duffy - Chief Business Officer

Jonathan Javitt - Founder, Chairman and Chief Scientist

Michael Abrams - Chief Financial Officer

Conference Call Participants

Jason Kolbert - D. Boral Capital

Thomas Shrader - BTIG

Vernon Bernardino - H.C. Wainwright

Ed Woo - Ascendiant Capital

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Monday, March, 17 2025.

I would now like to turn the conference over to Matthew Duffy, Chief Business Officer. Please go ahead.

Matthew Duffy

Thank you, Joelle, and good morning, everyone. Welcome to our call.

Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U. S. Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made during this call speak only as of the day hereof, and the company undertakes no obligation to update or revise the forward looking statements.

Information presented on this call is contained in the press release issued this morning and the company's Form 10-K, which was filed on Friday and may be accessed from the Investor page of the NRx Pharmaceuticals, Inc. website....

Read the full article on Seeking Alpha

For further details see:

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript
NRX Pharmaceuticals Inc. Warrant

NASDAQ: NRXPW

NRXPW Trading

3.32% G/L:

$0.028 Last:

76,526 Volume:

$0.027 Open:

mwn-alerts Ad 300

NRXPW Latest News

NRXPW Stock Data

$51,919,863
21,256,498
N/A
13
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmington

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App